



LUND UNIVERSITY

Post-translational modifications in proteins involved in blood coagulation.

Hansson, Karin M; Stenflo, Johan

Published in:
Journal of Thrombosis and Haemostasis

DOI:
[10.1111/j.1538-7836.2005.01478.x](https://doi.org/10.1111/j.1538-7836.2005.01478.x)

2005

[Link to publication](#)

Citation for published version (APA):
Hansson, K. M., & Stenflo, J. (2005). Post-translational modifications in proteins involved in blood coagulation. *Journal of Thrombosis and Haemostasis*, 3(12), 2633-2648. <https://doi.org/10.1111/j.1538-7836.2005.01478.x>

Total number of authors:
2

General rights

Unless other specific re-use rights are stated the following general rights apply:
Copyright and moral rights for the publications made accessible in the public portal are retained by the authors and/or other copyright owners and it is a condition of accessing publications that users recognise and abide by the legal requirements associated with these rights.

- Users may download and print one copy of any publication from the public portal for the purpose of private study or research.
- You may not further distribute the material or use it for any profit-making activity or commercial gain
- You may freely distribute the URL identifying the publication in the public portal

Read more about Creative commons licenses: <https://creativecommons.org/licenses/>

Take down policy

If you believe that this document breaches copyright please contact us providing details, and we will remove access to the work immediately and investigate your claim.

LUND UNIVERSITY

PO Box 117
221 00 Lund
+46 46-222 00 00

The following pages constitute the final, accepted and revised manuscript of the article:

Hansson, K and Stenflo, J

“Post-translational modifications in proteins involved in blood coagulation”

J Thromb Haemost. 2005 Aug 26; [Epub ahead of print]

Publisher: Blackwell.

Use of alternative location to go to the published version of the article requires journal subscription.

Alternative location: <http://dx.doi.org/10.1111/j.1538-7836.2005.01478.x>

Post-translational Modifications in Proteins Involved in Blood Coagulation

Hansson, K. and Stenflo, J.

Department of Clinical Chemistry, Lund University, University Hospital Malmö S-20502
Malmö, Sweden

Correspondence: Karin Hansson, Department of Clinical Chemistry, Lund University,
University Hospital, Malmö, S-205 02 Malmö, Sweden. Tel. 46-40-337226; Fax: 46-40-
929023; E-mail: Karin.Hansson@klkemi.mas.lu.se

Keywords: β -hydroxyasparagine, β -hydroxyaspartic acid, γ -carboxyglutamic acid, N-linked glycosylation, O-linked glycosylation, phosphotyrosine, sulfotyrosine

Introduction

Blood coagulation and its anticoagulant counterpart, the protein C system, proceed via the formation of cell-associated macromolecular enzyme complexes that interact in a precisely regulated manner. In the final step of coagulation thrombin is generated, which cleaves soluble fibrinogen to form the insoluble fibrin monomers that constitute the structural foundation of a blood clot [1,2]. Post-translational protein modifications play pivotal roles in both blood coagulation and the protein C anticoagulant system.

The relatively high concentration of most of the blood coagulation proteins enabled many of them to be purified to homogeneity some thirty to forty or more years ago. Advanced chemical characterization and protein sequencing became possible, which in time resulted in the identification of several post-translational amino acid modifications. These developments, and the interest in blood coagulation and coagulation disorders, led to the identification of three types of modified amino acids in coagulation proteins before they were found in proteins belonging to other systems. The first was γ -carboxyglutamic acid (Gla) in 1974, which is formed by vitamin K-dependent γ -carboxylation of glutamic acid residues [3-5]. Then followed *erythro*- β -hydroxyaspartic acid (Hya) and *erythro*- β -hydroxyasparagine (Hyn), which are formed by hydroxylation of aspartic acid and asparagine residues, respectively [6,7]. At that time, blood coagulation was described by the so-called cascade scheme [2,8,9]. It called attention to the signal amplification that is required to obtain the amounts of thrombin necessary to convert soluble fibrinogen to insoluble fibrin and it illustrated the role of enzymatically active macromolecular complexes. Moreover, the importance of binding to cell surfaces, i.e. that the coagulation process to a large extent is an example of chemistry in two (rather than three) dimensions was only beginning to emerge.

The identification of Gla, stimulated by a desire to learn about the mode of action of warfarin [10], indirectly led to the purification of protein C, and a few years later protein S and thrombomodulin [11-15]. With these proteins identified, and with the novel cofactor role of factor V established as a result of research on resistance to activated protein C, most of the key components of the protein C anticoagulant system had been identified [16]. Lately the coagulation system has been refined due to new insights into the roles of the various cell types involved [17]. Hence, the initiation phase of coagulation is now known to commence on tissue factor-bearing cells such as macrophages, followed by an amplification phase involving platelet activation and activation of factors V and VIII. In the third phase, the propagation phase, bulk amounts of thrombin are generated on the surface of newly activated platelets [17]. The activity of the serine proteases generated during this sequence of reactions is under

rigorous control, mediated by the tissue factor pathway inhibitor and antithrombin; the latter a so-called serpin [18]. Likewise, activated protein C (APC) and its cofactors, protein S and factor V, regulate the activity of the activated forms of two homologous cofactors, factors VIIIa and Va [19].

In this review we describe the post-translational modifications that occur in blood coagulation proteins and, where known, their functional implications. In the integrated defense system there are no borders between blood coagulation, the complement system, and the immune system. We have, however, taken a conservative approach and will deal only with those modifications that are found in the traditional coagulation factors, including the protein C anticoagulant system and antithrombin. Seven years ago an excellent review of the same field was published [20].

Domain organization of coagulation proteins

Coagulation factors VII, IX, X, and prothrombin in the coagulation cascade, and protein C and proteins S of the protein C anticoagulation system require vitamin K for proper biosynthesis. These proteins contain several distinct domains starting with an N-terminal domain of about 45 amino acid residues that includes nine to twelve γ -carboxylated glutamic acid (Gla) residues (Fig. 1) [21,22]. In factors VII, IX, X, and protein C the Gla domain is followed by two epidermal growth factor (EGF)-like domains, and a C-terminal serine protease domain. Prothrombin differs from these proteins in that it contains two kringle domains in place of the two EGF-like domains. Moreover, prothrombin contains a tetradecapeptide loop structure between the Gla domain and the first kringle domain. In protein S, the Gla domain is followed by a thrombin-sensitive region, four EGF-like domains, and a SHBG-like domain. The genes encoding these six multi-domain Gla proteins are believed to have been assembled by exon-shuffling via intronic recombination [23]. A signature of the exon-shuffling events is the presence of “symmetrical” domains, i.e. domains that are flanked by introns of the same phase class. The introns that participated in the assembly process are all of class 1. Each domain is encoded by one or more exons. For instance, the EGF-like domains are each encoded on separate exons flanked by class 1 introns, whereas the Gla domain (including the propeptide; see γ -carboxyglutamic acid section) is encoded by two exons. The outer intron splice junctions of the two Gla exons are of class 1 whereas the inner is of class 0, thus demonstrating that the Gla domain has most likely been recruited as a unit.

Factor V and factor VIII function as essential cofactors for the proteolytic activation of prothrombin and factor X, respectively. These cofactors have a conserved domain organization (A1-A2-B-A3-C1-C2) and share about 40% amino acid identity in their A- and C-domains (Fig. 2) [24,25]. The exon-intron organizations of factors V and VIII are almost identical and analysis of their amino acid sequences suggests that the genes encoding these cofactors have evolved through a process of gene duplication and/or exon-shuffling [26]. The three A-domains are homologous to the A-domain of ceruloplasmin, the major copper-binding protein in plasma, whereas the two C-domains are homologous to the discoidin family of proteins that was first described as phospholipid-binding lectins from *Dictyostelium discoideum* [27,28]. In contrast, the heavily glycosylated B-domains of factor V and factor VIII are non-homologous and share no obvious sequence similarity to any known protein.

von Willebrand factor (vWF) is a multimeric protein that promotes platelet adhesion at sites of vascular injury as well as serving as a carrier protein for factor VIII [29]. vWF dimers are assembled in the ER from pairs of ~250-kDa mature subunits via disulfide linkages within the C-terminal region of the polypeptide chains. The dimers are transported to the Golgi apparatus where multimers are formed by inter-dimeric disulfide linking of N-terminal domains and propeptide cleavage [29]. Only large multimeric forms of vWF are haemostatically active. The mature vWF subunit is composed of five types of repeating domains (A–D, and CK) arranged from the N- to the C-terminus in the order: D'-D3-A1-A2-A3-D4-B1-B2-B3-C1-C2-CK (Fig. 3) [30]. The structure implies that duplication events and/or exon-shuffling mechanisms have played an important role in the origin of the vWF gene.

Signal peptide cleavage

Proteins that are destined either to be secreted to the extracellular space, to remain in the cisternal space of the endoplasmic reticulum (ER), or become integral membrane proteins generally have an N-terminal signal peptide. The signal peptide is instrumental in the association of the nascent peptide chain with the cytosolic side of the ER. Insertion of the signal peptide into the ER initiates translocation of the peptide across the membrane [31,32]. While the protein is translocated through the ER membrane the signal peptide is cleaved off by a signal peptidase. The common structure of signal peptides consists of a positively charged region at the N-terminus, followed by a hydrophobic region and a neutral but polar C-terminal region. The residues at positions –1 and –3 (relative to the cleavage site) must be small and neutral for cleavage to occur correctly [33]. A number of mutations within or near

signal peptides that alter the processing of human blood coagulation proteins have been reported. For instance, in factor X^{Santo Domingo} there is a point mutation at position -3 of the signal peptide region that results in the substitution of Arg for Gly [34,35]. This substitution precludes signal peptide cleavage and, hence, proper secretion of the factor X protein, resulting in a severe bleeding disorder. Another naturally occurring mutation at position -3 (Val-3Glu) has been reported in antithrombin^{Dublin}. This substitution redirects signal peptide cleavage to a new site two residues further toward the C-terminus of the protein [36]. This mutation does not appear to cause any pathological condition. Other examples of mutations in signal peptides that lead to defective secretion of the protein can be found in the FVIII and FIX databases [37,38].

Coagulation factor XIII is a transglutaminase that catalyzes the formation of covalent cross-links in fibrin clots [39]. It is a tetrameric protein complex composed of two A-subunits and two B-subunits. The B-subunit serves as a carrier for the catalytic A-subunit in plasma. The A-subunit is secreted, though it lacks a conventional N-terminal signal peptide sequence for translocation into the ER. Recent studies have shown that several extracellular proteins can be exported without a classical N-terminal signal peptide [40]. However, the pathways used for exporting these proteins are still poorly understood.

γ-Carboxyglutamic acid

The vitamin K antagonist warfarin was introduced as an anticoagulant therapy in the early 1940's. Like dietary vitamin K deficiency, this drug induces a reduction of the biological activity of the vitamin K-dependent proteins in blood plasma [10]. With the advent of new immunochemical techniques it was observed that this was due to a progressive reduction in concentration of the "normal" biologically active form of the protein, for instance prothrombin, and a concomitant increase in concentration of an "abnormal", inactive form [41-43]. In contrast to the normal form, the abnormal one did not bind Ca²⁺ ions. These observations initiated research that led to the identification of the Ca²⁺-binding amino acid, γ-carboxyglutamic (Gla), the post-translationally modified amino acid that is characteristic of all proteins that depend on vitamin K for normal biosynthesis [3-5,44].

In vertebrates most vitamin K-dependent proteins are coagulation factors that all have an N-terminal so-called Gla domain that is about 45 amino acid residues long and contains from nine to twelve Gla residues (Fig. 4A, Table 1) [22,45]. The Gla domain is found in prothrombin and factors VII, IX, X, which all belong to the traditional coagulation system. Proteins C and S of the protein C anticoagulant system also contain Gla domains [46,47].

Other Gla domain-containing proteins include protein Z, a regulator of blood coagulation [48] and Gas6, a homologue of protein S that appears to be a regulator of apoptosis [49]. There are also four recently identified Gla domain-containing transmembrane proteins termed proline-rich Gla protein (PRGP) 1 and 2, and transmembrane Gla protein (TMG) 3 and 4. The function of these membrane proteins, which appear to have their Gla domains located extracellularly, is unknown [50,51]. Most of the soluble Gla domain-containing proteins are almost exclusively synthesized in the liver. It should also be mentioned that in addition to the Gla domain-containing proteins there are two Gla proteins that regulate tissue mineralization: bone Gla protein (osteocalcin; with three Gla residues) and matrix Gla protein (five Gla residues) [52,53].

Coagulation factors or other proteins with Gla domains homologous to those found in the human coagulation factors have been identified in the vertebrate lineage as early as the tunicate *Halocynthia* [54,55]. Gla residues, formed by a vitamin K-dependent γ -carboxylation system similar to that in vertebrates, have also been found in certain neurotoxins isolated from molluscs of the genus *Conus* [56]. However, the molluscan peptides do not contain a Gla domain. A functional vitamin K-dependent carboxylase has also been found in *Drosophila melanogaster* [57].

The vitamin K-dependent carboxylase is an integral membrane protein resident in the ER [58-61]. The human carboxylase cDNA has been cloned and expressed. It encodes a 758-residue polypeptide that appears to span the ER membrane at least five times. Although the reaction has not yet been entirely clarified, it is assumed that the carboxylase converts the reduced (dihydroquinone) form of vitamin K to a peroxide intermediate that is further converted to a basic dialkoxide. The dialkoxide abstracts a proton from the γ -carbon of an appropriate glutamyl residue, followed by CO₂ addition to the glutamyl carbanion (Fig. 4B) [61]. In the next step the dialkoxide collapses to a 2,3-epoxide. The epoxide is reduced back to the dihydroquinone form of vitamin K in two steps by a vitamin K epoxide reductase. The coumarin warfarin exerts its anticoagulant effect by inhibiting the epoxide reductase, resulting in the synthesis of biologically inactive uncarboxylated and partially carboxylated forms of the vitamin K-dependent proteins [62,63]. In addition, warfarin treatment reduces the total prothrombin concentration by about 30%, presumably due to increased intracellular degradation [42].

The Gla domain-containing proteins are synthesized as single polypeptide chains. An N-terminal signal peptide is followed by a propeptide of about 18 amino acids that terminates with a basic sequence such as Arg-Xxx-Lys/Arg-Arg that is recognized by the propeptide-

cleaving enzyme [64-66]. The propeptide is followed by the ≈ 45 residue-long Gla domain, in which all Glu residues are carboxylated irrespective of the sequence surrounding them (Fig. 4A). This specificity sets the carboxylase apart from other enzymes that mediate post-translational modifications, such as glycosylating or prolyl hydroxylating enzymes, which recognize a very particular amino acid sequence. The propeptide not only mediates binding of the substrate to the enzyme but also activates the enzyme [66,67]. This is illustrated when low-molecular-weight peptides (for instance Phe-Leu-Glu-Glu-Leu) are used as substrates for the carboxylase. The K_M for the reaction with such a substrate is in the millimolar range, but if the peptide is synthesized with an N-terminal propeptide extension the K_M is lowered about three orders of magnitude [68,69]. The K_M is reduced even if a synthetic propeptide which is not attached to the substrate is added [66]. It appears that the carboxylase reaction is processive in its nature, i.e. all Glu residues are carboxylated before the substrate is released from the enzyme [67,68]. The propeptide is removed by limited proteolysis in the Golgi apparatus by a propeptide processing enzyme that recognizes two conserved basic residues in the peptide [65].

The structure of the Ca^{2+} -saturated form of bovine prothrombin fragment 1 has been determined to a resolution of 2.2Å by X-ray crystallography [70]. More recently, the structure of human protein C (including the Gla domain) bound to the endothelial cell protein C receptor was solved to 1.55Å [71]. The prothrombin fragment 1 structure shows seven Ca^{2+} ions bound (Fig. 5). Cys residues 17 and 22 are linked by a disulfide bond and positioned adjacent to the side chains of Phe41, Trp42 and Tyr45 of the so-called hydrophobic stack region. Tyr45 is hydrogen-bonded to Cys17. The twelve N-terminal residues are folded into an Ω -like loop formed as a result of Gla residues ligating the seven Ca^{2+} ions. The N-terminus of the loop (Ala1) is completely buried and makes an ion-pair interaction with Gla residues. Indeed, in the presence of Ca^{2+} ions this amino group is protected from chemical modification by acylating reagents [72]. In this structure all but one of the Gla residues (Gla33) point to the interior of the domain where they ligate the Ca^{2+} ions. In contrast, three hydrophobic residues, Phe4, Leu5 and Val8, in the Ω loop are exposed to the solvent.

In a crystal structure of the Ca^{2+} -free form of bovine fragment 1 the only part of the Gla domain that diffracts is the C-terminal α -helix (residues 36 to 47), whereas the rest of the domain appears disordered [73]. Determination, by NMR spectroscopy, of the structure of a metal-free factor X fragment comprising the Gla domain and the N-terminal EGF-like domain shed some light on the nature of binding of Ca^{2+} to the Gla domain [74]. The structure showed that the α -helices were retained, albeit less well defined than in the Ca^{2+} -saturated form.

However, the N-terminal eleven residues were very mobile, with the two Gla residues exposed to solvent and the three hydrophobic residues (Phe4, Leu5 and Val8) clustered in the interior of the domain [45,74]. Similar results were obtained by NMR studies of a synthetic Gla domain from factor IX [75].

The dicarboxylate side chain of a Gla residue binds Ca^{2+} ions with low affinity, similar to that of malonate ($K_d \sim 30$ mM) [76]. Yet, the Gla domains of coagulation factors appear to be half-saturated at about 0.5 mM Ca^{2+} , and close to saturated at the physiological free Ca^{2+} concentration of ~ 1.2 mM [76-79]. The binding process can be followed by fluorescence emission spectroscopy due to the Ca^{2+} -induced repositioning of Phe40, Trp41 and Tyr44 (numbered in Fig. 4A) in the C-terminal so-called hydrophobic stack region of the Gla domain. The structural difference between the Ca^{2+} -saturated and metal-free forms of the Gla domain sheds light on the nature of the Ca^{2+} -induced structural transition. The conformational transition brings the solvent-exposed Gla residues into the interior of the domain, where they ligate seven Ca^{2+} ions (Fig. 5). Coupled to this conformational change is the translocation of Phe4, Leu5 and Val8 from inside the domain to a position on the surface, where the side chains are exposed to the solvent. The Ca^{2+} -induced structural transition brings Gla carboxylate groups into close proximity and hence electrostatic repulsion calls for highly cooperative metal ion binding [45].

The structure of the Ca^{2+} -saturated Gla domain explains the membrane-binding properties of Gla domain-containing coagulation factors. Binding of most Gla domain-containing proteins to phospholipid vesicles is optimal when about 25% of the phospholipid comprises a negatively charged species such as phosphatidyl serine, and the rest is phosphatidyl choline [80-82]. This mimics the composition of the part of the lipid bilayer that faces the interior of the cell, but which becomes exposed as a result of cell damage. Likewise, phosphatidyl serine becomes exposed when platelets are activated by, for instance, thrombin. Phospholipid vesicles of the appropriate composition lower the K_m for activation of prothrombin by factor Xa by two orders of magnitude [80]. Addition of factor Va increases the V_{\max} of the reaction greatly, leading to a total increase in reaction rate, as mediated by the phospholipid and the cofactor, of about 10^6 -fold. If, however, prothrombin with an uncarboxylated Gla domain is used as the substrate for factor Xa, no enhancement of the reaction rate is observed following the addition of phospholipid, as the Gla domain of the uncarboxylated prothrombin does not bind Ca^{2+} [43]. The Gla-mediated Ca^{2+} binding induces a conformation that is a prerequisite for lipid binding and for increasing the substrate concentration on the membrane surface. It thus allows the reactants to be concentrated on a

two-dimensional surface, which enables a transition in the reaction from three-dimensional to two-dimensional chemistry.

Experimental evidence indicates that Gla-mediated membrane binding is to a large extent hydrophobic in nature [83]. In the case of the prothrombin Gla domain, the hydrophobic side chains of Phe4, Leu5 and Val8 penetrate the membrane and seem to account for much of the binding energy. There is, however, also an electrostatic component involved, which may explain why though the amino acid sequences of the 34 N-terminal amino acids in the Gla domains of factor Xa and protein C differ at only five positions, factor Xa binds to membranes with a Kd of about 40 nM, whereas the Gla domain-mediated binding of bovine protein C exhibits a Kd of about 1.5 μ M [84]. Yet the amino acid sequence of the 34 N-terminal amino acids in the two Gla domains only differs in five positions. A recent X-ray structure of prothrombin fragment 1 has provided new knowledge that may explain these differences, in that it showed that the serine head group of phosphatidyl serine has multiple interactions with Ca^{2+} ions and Gla residues [85]. Particularly Ca5 and Ca6, and Gla17 and Gla21 (as well as Arg10 and Arg16) seem to be involved. These results also shed light on the phospholipid specificity of the vitamin K-dependent coagulation factors. A series of naturally occurring Gla domain mutations that cause defective membrane binding have also been described [44].

With more than three or four Gla residues missing the coagulation factors become non-functional, as the Gla domain cannot fold to the Ca^{2+} -induced biologically active conformation [86]. Hence, prothrombin and other vitamin K-dependent coagulation factors produced during warfarin treatment have an heterogeneous Gla content and consist of two populations of molecules: a biologically active one that has lost less than four Gla residues, and an inactive one that is severely under-carboxylated. The two populations are easily discernible by electrophoresis in Ca^{2+} -containing buffers.

β -hydroxyaspartic acid and β -hydroxyasparagine

EGF-like domains are phylogenetically old and are one of the most common types of domains found in extracellular and integral membrane proteins. Typically they are 45 amino acid residues long and have six Cys residues that are linked by disulfide bonds in a characteristic pattern (1-3, 2-4, and 5-6; Fig. 6) [22,87,88]. The structure is dominated by a major double-stranded β -hairpin and there is also a minor β -hairpin towards the C-terminus (Fig. 7).

About 25% of the EGF domains contain either one *erythro*- β -hydroxyaspartic acid (Hya) residue or one *erythro*- β -hydroxyasparagine (Hyn) residue [22,87,88]. Hya, first identified in the N-terminal EGF-like domain of protein C, is also found in the N-terminal domains of the homologous factors VII, IX and X, and in protein S (Fig. 1, Table 1) [22,87-89]. In protein S the N-terminal EGF domain has a Hya residue whereas each of EGF domains 2 through 4 has one Hyn residue (Fig. 6) [7].

EGF domains that possess a Hya/Hyn residue have a characteristic consensus sequence between the third and fourth Cys residues that is essential for hydroxylation, i.e. Cys-Xxx-Asp*/Asn*-Xxx₄-Tyr/Phe-Xxx-Cys, where an asterisk denotes a hydroxylated residue (Fig. 6A). The consensus sequence must form part of the major β -hairpin of an EGF-like domain with the Asp/Asn residue adjacent to the Tyr/Phe residue for hydroxylation to occur [22,87,88,90]. Hydroxylation of the Asp/Asn residue is often partial [89]. The Asp/Asn- β -hydroxylase is a dioxygenase, meaning that the enzyme reaction requires molecular oxygen and that one oxygen atom goes into the -OH group and the other into the co-substrate, 2-oxoglutarate, which is cleaved to form succinate and carbon dioxide (Fig. 6B) [90,91]. The enzyme thus belongs to the same group of enzymes as prolyl-4-hydroxylase. However, unlike prolyl-4-hydroxylase, the Asp/Asn- β -hydroxylase does not require ascorbate for biological activity [92]. The Asp/Asn- β -hydroxylase has been cloned and studied in detail [91]. Knockout mice that lack the enzyme get developmental defects and have an increased incidence of gastrointestinal neoplasms [93].

Early on it was found that Hya/Hyn-containing EGF-like domains bind Ca^{2+} [94-97]. And indeed, the consensus sequence required for β -hydroxylation occurs only in those EGF domains where the Ca^{2+} -ligating amino acids immediately N-terminal of the first Cys residues are conserved (Figs. 6 and 7) [22,88,97]. An isolated EGF-like domain exhibits a K_d for Ca^{2+} binding of about 1 mM, but when linked to an N-terminal neighbor, the affinity increases 10 to 100-fold [22].

Hya/Hyn-mediated Ca^{2+} -binding to the N-terminal EGF domain is functionally important and in, for instance, factor X it serves to orient the adjacent Gla domain, relative to the EGF-like domain, in a manner that is commensurate with biological activity [74,98-101]. In the absence of Ca^{2+} the two domains are mobile relative to each other. Naturally occurring mutations that affect the Ca^{2+} -ligands reduce the metal ion affinity of the domain, which in factor IX leads to a reduced biological activity and haemophilia [88]. In protein S the Ca^{2+} -binding orients the four EGF-like domains relative to each other [22]. The protein S studies

have also shown that the Ca^{2+} -binding site in EGF-like domains is very versatile, in that the Ca^{2+} affinity can vary several orders of magnitude from one domain to another [22,100]. Although the Hya/Hyn residues are critical for Ca^{2+} -binding the –OH group per se does not appear to be involved in its function [102].

Recently it was found that the transcription factor, hypoxia-inducible factor 1a, has a β -hydroxylated Asn residue at position 803. Hydroxylation is mediated by a 2-oxoglutarate-dependent dioxygenase, but unlike Hya/Hyn in EGF-like domains, which have the *erythro* isomer this enzyme produces the *threo* isomer [103,104].

Glycosylation

Glycosylation is the most common post-translational modification observed in extracellular and integral membrane proteins. It is required for the proper folding and efficient secretion of many extracellular proteins [105,106]. The carbohydrate moieties not only stabilize folded domains but also provide polar surface groups that prevent aggregation of folding intermediates and allow newly synthesized polypeptide chains to interact with ER chaperones and enzymes. Glycosylation also plays a significant role in determining the plasma half-life and biological activity of many proteins [107-109]. Almost all of the proteins that transit the secretory pathway of eukaryotic cells, including the coagulation factors, acquire one or more oligosaccharide units by the action of enzymes of the ER and Golgi apparatus (albumin and prealbumin are notable exceptions). Sugars are attached to the protein through either the side chain amide nitrogen of an asparagine residue (N-linked glycosylation) or the oxygen atom in the side chain of serine or threonine residues (O-linked glycosylation).

The N-linked sugars are added as core units of 14 saccharides ($\text{Glc}_3\text{Man}_9\text{GlcNAc}_2$) to Asn within specific Asn-X-Ser/Thr sequences when the polypeptide chains enter the lumen of the ER. The third amino acid in the consensus sequence has been found to influence the glycosylation process, with Thr associated with a higher degree of glycosylation than Ser [110]. The reaction is catalyzed by a membrane-bound oligosaccharide transferase [106]. The Asn-X-Ser/Thr consensus sequence is necessary, but not sufficient, to direct glycosylation. It has been found that glycosylation is favored when the sequence is exposed on β -turns, or other turns or loop structures [111]. A few examples of N-glycosylation are known within an Asn-X-Cys stretch, for instance in protein C and vWF [112-114]. For a more detailed description of the processing of N-linked glycans in the ER the reader is referred to a recent review [106].

O-linked glycosylation of a polypeptide occurs exclusively in the Golgi apparatus by serial addition of monosaccharide units, typically beginning with N-acetyl galactosamine. For a detailed description of the biosynthesis of O-linked carbohydrates the reader is referred to reference [115]. The EGF-like domains of a small number of secreted proteins provide an exception in that the first monosaccharide to be added is either a fucose or glucose residue [116,117]. O-linked glucose modifications have been associated with a consensus site located between the first and second conserved Cys residues of the EGF domain (Cys₁-X-Ser-X-P-Cys₂), whereas the O-linked fucose consensus site (Cys₂-X-X-Gly-Gly-Ser/Thr-Cys₃) resides between the second and third conserved Cys residues.

The two homologous cofactors, factors V and VIII, are extensively O-, and N-glycosylated, especially within the B-domains [118]. Though their B-domains share no amino acid sequence similarity they have an equal abundance of N-linked oligosaccharide chains (Fig. 2, Table 1). The carbohydrates have been shown to be important for secretion, as inhibition of N-linked glycosylation by treatment with tunicamycin dramatically reduces the secretion of both factor V and factor VIII [119,120]. In more recent studies it has been suggested that the high mannose-containing N-linked oligosaccharides of the B-domain of factor VIII represent the primary interaction site for protein chaperones calnexin and calreticulin and are responsible for the interaction with the mannose lectin LMAN1 [121-123]. The N-linked oligosaccharides can thus participate in the folding interactions within the ER as well as facilitate ER-Golgi transport. Moreover, recent studies have shown that the carbohydrate moieties on procofactor V, but not on the derived cofactor, factor Va, substantially alter its susceptibility to APC-catalyzed inactivation [124,125]. Thus, the N-linked carbohydrates associated with the heavy chain region appear to protect factor V, but not factor Va, from APC-catalyzed inactivation.

Thrombin-activated factor Va appears as two isoforms which have slightly different molecular masses and charges; factor Va1 and factor Va2 [126]. The heterogeneity is caused by partial glycosylation at Asn2181 in the C2 domain of the light chain, due to the presence of Ser rather than Thr at the third position in the glycosylation consensus sequence [127,128]. The glycosylated factor Va1 has been shown to possess a lower affinity for membrane surfaces, resulting in reduced procoagulant activity, particularly at low phospholipid concentrations.

Recently, a naturally occurring mutation that is associated with venous thrombosis was described in factor V (Ile359Thr; factor V^{Liverpool}) [129]. The mutation creates a new potential consensus sequence for N-glycosylation within the factor V heavy chain. The additional

carbohydrate chain at position 359 interferes with the interaction of factor Va with APC and protein S [130]. As a result, anticoagulation is affected by a dual mechanism; first, the APC-mediated down-regulation of the mutant is impaired, both in the presence and absence of protein S; and second, the mutant factor V is a poor APC cofactor for the inactivation of factor VIIIa. Naturally occurring mutations that create new potential glycosylation sites have also been reported in factor VIII (Met1772Thr and Ile566Thr), where the additional carbohydrates are responsible for the pathogenesis of severe haemophilia A [131]. How these carbohydrate side chains affect the biological activity of the protein is not known.

Factor VIII circulates in plasma in a non-covalent complex with vWF. This interaction extends the survival of factor VIII in the circulation by protecting it from inactivation by APC and factor Xa. Mature vWF is composed of identical disulfide-linked subunits, each with twelve N-linked and ten O-linked oligosaccharides (Fig. 3, Table 1) [29,114]. The N-linked oligosaccharides are unusual compared to those of other plasma proteins in that they contain ABO blood group structures [132]. One or both of the oligosaccharides attached to Asn384 and Asn468 are sulfated [133]. Inhibition of N-linked glycosylation by tunicamycin has been shown to affect the conformation of vWF in such a way that dimerization cannot occur and the resulting monomeric vWF molecules are retained in the ER [134].

Tissue factor (TF), the cofactor which in complex with circulating factor VIIa initiates coagulation, has three N-linked glycosylation sites: Asn11, Asn124, and Asn137. The function of the carbohydrates is unclear, as they may be removed without loss of activity [135]. In human factors VII and IX an O-linked glucose and an O-linked fucose are both attached to the first EGF-like domain (Fig. 1, Table 1). In the case of factor IX, attachment of additional sugar units to the O-linked fucose at Ser61 gives rise to a tetrasaccharide structure (Sia- α 2,6-Gal- β 1,4-GlcNAc- β 1,3-Fuc- α 1-O-Ser) identical to those found in the Notch1 protein [117,136,137]. The O-fucose glycans in the extracellular domain of Notch1 have been reported to be essential for protein signalling and function [137,138]. The fucose residue attached to Ser60 of factor VII has been found to slightly increase the Ca²⁺ affinity of the FVII-EGF1 module but it seems to have no major effect on the conformation of the module [139]. The O-linked glucose modifications in factors VII and IX (at Ser52 and Ser53, respectively) are in a di- or trisaccharide form having the structure Xyl₂-Glc-O-Ser [140]. The disaccharide form lacks the terminal xylose. A functional role for these unusual O-glycans on factors VII and IX remains to be established.

In addition to the Ser-linked carbohydrates present in the first EGF module, human factor IX is partially O-glycosylated at Thr159, Thr169, Thr172 and Thr179 [141,142]. There

are also sites for attachment of N-linked oligosaccharides at Asn residues 157 and 167 in the activation peptide of factor IX [64]. There is little definitive data on the importance of these glycans.

The activation peptide of human factor X has N-linked carbohydrates attached to Asn181 and Asn191, and O-linked carbohydrates linked to Thr159 and Thr171 [143-145]. Conversion of factor X to factor Xa by cleavage at Arg194 results in the release of a 52-residue glycosylated activation peptide. Whether the carbohydrates in the activation peptide domain of factor X are important for its activation is not fully understood. Initial studies suggested a role in factor X activation, but this could not be corroborated by more recent studies [145-149].

In human prothrombin, three of the four potential N-glycosylation sites are utilized; those at Asn78, Asn100 and Asn373 [150]. A recent report has suggested that the N-linked oligosaccharide structures contribute to the stability of the prothrombin precursor during processing in the ER [151].

The heavy chain of human protein C contains three N-linked carbohydrates, and the light chain one [152]. Studies have shown that the carbohydrates at each of these sites influence the secretion, proteolytic processing and rate of activation by thrombin [153,154]. The carbohydrate at position Asn97 in the light chain is important for efficient secretion of protein C, whereas glycosylation at Asn248 affects processing at the internal Lys-Arg cleavage site [153]. The non-enzymatic cofactor to APC, protein S, is N-glycosylated at three positions: Asn458, Asn468, and Asn489, all within the C-terminal LG2 domain of the SHBG region [155]. About 70% of protein S in the circulation is bound to C4BP, a regulator of the complement system [156]. Only free protein S can act as a cofactor for APC [157]. *In vitro* studies have shown that the N-linked carbohydrates have little influence on the activity of human protein S and do not interfere with binding to C4BP [155,158]. In protein S^{Heerlen} (Ser460Pro), the normal glycosylation of Asn458 does not occur [159]. This mutation is frequently found among individuals diagnosed with protein S deficiency type III, which is characterized by low free protein S levels but a normal total plasma concentration of protein S. Recombinant wild type protein S and protein S^{Heerlen} are equally active as APC cofactors in the inactivation of wild type factor Va. However, when FVa^{Leiden}, carrying the mutation Arg506Gln, is used as the APC substrate, protein S^{Heerlen} displays poor APC cofactor activity [160]. This suggests a synergy between protein S^{Heerlen} and factor V^{Leiden} that might result in an increased risk of thrombophilia in individuals carrying both genetic factors [160].

Antithrombin, the major inhibitor of plasma proteinases, exhibits two isoforms, α - and β -, due to differences in glycosylation. The predominant α -isoform, which accounts for ~90% of the inhibitor, is glycosylated at all four potential N-glycosylation sites (Asn96, Asn135, Asn155, and Asn192), whereas the minor β -isoform lacks carbohydrate at Asn135 [161-163]. Incomplete glycosylation of Asn135 derives from the presence of Ser rather than Thr at the third position of the Asn-X-Thr/Ser consensus sequence for core oligosaccharide addition [164]. Of the two isoforms, β -antithrombin has the higher affinity for heparin and has been suggested to be the major inhibitor *in vivo* [162,165,166]. The carbohydrate at Asn135 in α -antithrombin impedes the second step in the two-step mechanism of antithrombin-heparin binding, i.e. the heparin-induced conformational change, resulting in a difference in heparin affinity between the two isoforms [167]. It has been found that recombinant antithrombin lacking any of the four carbohydrates displays an increased heparin affinity [168]. Similar observations have been made for the protein C inhibitor, in that the heparin affinity is increased if each of the Asn-linked glycans at positions Asn230, Asn243, and Asn319 is eliminated [169]. At least three naturally occurring variants of antithrombin that have alterations in the number of glycan chains have been identified [170-172]. The first variant, which is similar to β -antithrombin, is caused by the mutation Asn135Thr and was isolated from an asymptomatic individual with antithrombin deficiency [170]. The second variant (Ile7Asn), which has a lowered affinity for heparin, and the third variant (Ser82Asn), which is secreted at a reduced rate, possess an additional fifth glycosylation site [171,172]. Removal of the terminal sialic acids from antithrombin does not affect its specific activity but drastically decreases the *in vivo* half-life of the protein [162,173,174].

Thrombomodulin, which plays an essential role as a cofactor in the thrombin-catalyzed activation of PC, has several potential N- and O-linked glycosylation sites [175]. It is a membrane-bound protein with EGF-like domains that mediate binding to thrombin. Binding changes the specificity of thrombin and converts it from a coagulant to an anticoagulant enzyme. Experimental evidence has indicated that a glycosaminoglycan moiety attached to thrombomodulin in the Ser/Thr-rich domain located between the sixth EGF module and the transmembrane domain provides a secondary thrombin-binding site which participates in PC activation. This glycan is also believed to stimulate inactivation of thrombin by antithrombin and the protein C inhibitor. For more detailed information about glycosylating enzymes the reader is referred to references [106, 115].

Tyrosine sulfation

Tyrosine sulfation is a post-translational modification that takes place in the *trans*-Golgi apparatus. The enzyme tyrosylprotein sulfotransferase (TPST) catalyzes the transfer of sulfate from the universal sulfate donor 3'-phosphate 5'-phosphosulfate (PAPS) to the hydroxyl group of a peptidyl tyrosine residue to form a tyrosine O⁴-sulfate ester and 3', 5'-ADP [176]. Human factor V and factor VIII have several sulfated Tyr residues while factor IX is sulfated at a single site (Tyr 155; Table1) [177-180]. Sulfation of factor V is required for full procoagulant activity, as inhibition of tyrosine sulfation by sodium chlorate results in a cofactor molecule with about 80% reduced activity [181]. The reduced activity has been attributed to slower thrombin-mediated activation and to a reduced intrinsic cofactor activity of factor Va. Likewise, tyrosine sulfation of factor VIII is required for full procoagulant activity as well as for optimal binding to vWF [178,182]. Sulfation of Tyr1680 in factor VIII appears to be crucially important for haemostasis as a point mutation in the factor VIII gene leading to the amino acid substitution Tyr1680Phe is associated with haemophilia A [183]. Based on studies where selected Tyr residues in factor VIII were mutated to Phe, it was suggested that sulfation of Tyr346 and Tyr1664 accelerate the rate of thrombin activation and that sulfation at Tyr718, Tyr719, and Tyr723 increases the intrinsic cofactor activity of factor VIIIa [184]. In agreement with this, a naturally occurring Tyr346Cys mutation results in a haemophilia phenotype [185].

Phosphorylation

Protein phosphorylation is one of the most common post-translational modifications occurring in animal cells. The vast majority of phosphorylation events occur intracellularly and relate to signal transduction. The phosphorylation reaction is catalyzed by a group of protein kinases that transfer a phosphate group from ATP onto the hydroxyl group of an amino acid side chain in a protein. In animal cells the side chains of Ser, Thr, and Tyr may be subject to phosphorylation, though there is some possibility that histidine may also be a substrate. Phosphorylation has been observed in coagulation factors V, VIII, IX and prothrombin (Table 1) [186,187]. Factor Va is phosphorylated on the heavy chain at Ser692 by a membrane-associated platelet casein kinase II (CKII) and at two sites in the light chain by a platelet-derived protein kinase C isoform, whereas factor VIII contains phosphorylation sites at Thr351 and Ser1657 [187-189]. Phosphorylation of the heavy chain of factor Va at Ser692 increases the rate of inactivation of the cofactor by APC and has therefore been suggested to play a role in the down-regulation of coagulation [189].

Propeptide processing

In addition to signal peptide cleavage, which occurs during or shortly after translocation across the ER membrane, many proteins require further proteolytic processing for complete maturation and full biological activity. The cleavage of the propeptide from pro-proteins occurs in the *trans*-Golgi compartment, just prior to secretion of the protein from the cell. In the case of the vitamin K-dependent proteins and vWF, propeptide cleavage is most likely catalyzed by one or more subtilisin-like propeptidase enzymes. One candidate enzyme is PACE (Paired basic Amino acid Cleaving Enzyme), which has been shown to be able to remove the propeptide from vWF, factor IX, and protein C. Cleavage occurs C-terminal to an Arg-Xxx-Lys/Arg-Arg consensus motif [190-192]. The propeptide of the vitamin K-dependent coagulation factors mediates binding to the γ -glutamyl carboxylase (see γ -carboxyglutamic acid section). Naturally occurring mutations that disrupt the propeptide cleavage site in factor VII, factor IX, protein C, or protein S all result in secreted proteins with severely reduced biological activity [193-196]. If the propeptide is retained it prevents the Gla domain from attaining the native Ca^{2+} -bound conformation needed for normal membrane binding. For instance, the absence of propeptide processing in two factor IX variants, factor IX^{Cambridge} (Arg-1Ser) and factor IX^{San Dimas} (Arg-4Gln), causes severe haemophilia [196,197].

In endothelial cells, the assembly of multimeric vWF molecules proceeds, to a large extent, prior to cleavage of the large 741-residue propeptide. The propeptide serves a major role in the multimerization process in the *trans*-Golgi compartment by promoting the formation of disulfide bonds between vWF-dimers. The polymerization process utilizes Cys-Xxx-Xxx-Cys motifs in the propeptide, which mirror the signature active site motif observed in oxidoreductase family members [198,199]. Removal of the propeptide from factor VIII has been shown to be crucial for its interaction with the N-terminal D'-domain of vWF [200].

Acknowledgement

The authors are thankful to Dr. Mark Brown for providing figure 5 and for critically reading the manuscript and to Dr. Torbjörn Drakenberg for providing figure 7.

References

1. Kalafatis M, Egan JO, van't Veer C, Cawthorn KM, Mann, KG. The regulation of clotting factors. *Crit Rev Eukaryot Gene Expr* 1997; **7**: 241-80.
2. Davie EW. A brief historical review of the waterfall/cascade of blood coagulation. *J Biol Chem* 2003; **278**: 50819-32.
3. Stenflo J, Fernlund P, Egan W, Roepstorff P. Vitamin K dependent modifications of glutamic acid residues in prothrombin. *Proc Natl Acad Sci USA* 1974; **71**: 2730-3.
4. Nelsestuen GL, Zytkevich TH, Howard JB. The mode of action of vitamin K. Identification of γ -carboxyglutamic acid as a component of prothrombin. *J Biol Chem* 1974; **249**: 6347-50.
5. Magnusson S, Sottrup-Jensen L, Petersen TE, Morris HR, Dell A. Primary structure of the vitamin K-dependent part of prothrombin. *FEBS Lett* 1974; **44**: 189-93.
6. Drakenberg T, Fernlund P, Roepstorff P, Stenflo J. β -Hydroxyaspartic acid in vitamin K-dependent protein C. *Proc Natl Acad Sci USA* 1983; **80**: 1802-6.
7. Stenflo J, Lundwall Å, Dahlbäck B. β -Hydroxyasparagine in domains homologous to the epidermal growth factor precursor in vitamin K-dependent protein S. *Proc Natl Acad Sci USA* 1987; **84**: 368-72.
8. Davie EW, Ratnoff OD. Waterfall sequence for intrinsic blood clotting. *Science* 1964; **145**: 1310-2.
9. MacFarlane RG. An enzyme cascade in the blood clotting mechanism, and its function as a biochemical amplifier. *Nature* 1964; **202**: 498-9.
10. Link KP. The discovery of dicumarol and its sequels. *Circulation* 1959; **1**: 97-107.
11. Stenflo J. A new vitamin K-dependent protein. Purification from bovine plasma and preliminary characterization. *J Biol Chem* 1976; **251**: 355-63.
12. Esmon CT, Stenflo J, Suttie JW. A new vitamin K-dependent protein: a phospholipid-binding zymogen of a serine esterase. *J Biol Chem* 1976; **251**: 3052-6.
13. Di Scipio RG, Hermodson MA, Yates SG, Davie EW. A comparison of human prothrombin, factor IX (Christmas factor), factor X (Stuart factor), and protein S. *Biochemistry* 1977; **16**: 698-706.
14. Walker FJ. Regulation of activated protein C by a new protein. A possible function for bovine protein S. *J Biol Chem* 1980; **255**: 5521-4.
15. Esmon CT, Owen WG. Identification of an endothelial cell cofactor for thrombin-catalyzed activation of protein C. *Proc Natl Acad Sci USA* 1981; **78**: 2249-52.
16. Dahlbäck B. Blood coagulation. *Lancet* 2000; **355**: 1627-32.
17. Monroe DM, Hoffman M, Roberts HR. Platelets and thrombin generation. *Arterioscler Thromb Vasc Biol* 2002; **22**: 1381-9.
18. Gettins PG. Serpin structure, mechanism, and function. *Chem Rev* 2002; **102**: 4751-804.
19. Dahlbäck B. Progress in the understanding of the protein C anticoagulant pathway. *Int J Hematol* 2004; **79**: 109-16.
20. Kaufman RJ. Post-translational modifications required for coagulation factor secretion and function. *Thromb Haemost* 1998; **79**: 1068-79.
21. Furie B, Furie BC. The molecular basis of blood coagulation. *Cell* 1988; **53**: 505-18.
22. Stenflo J. Contributions of Gla and EGF-like domains to the function of vitamin K-dependent coagulation factors. *Crit Rev Eukaryot Gene Expr* 1999; **9**: 59-88.
23. Patthy L. Evolution of the proteases of blood coagulation and fibrinolysis by assembly from modules. *Cell* 1985; **41**: 657-63.
24. Kane WH, Davie EW. Cloning of a cDNA coding for human factor V, a blood coagulation factor homologous to factor VIII and ceruloplasmin. *Proc Natl Acad Sci USA* 1986; **83**: 6800-4.

25. Toole JJ, Knopf JL, Wozney JM, Sultzman LA, Buecker JL, Pittman DD, Kaufman RJ, Brown E, Shoemaker C, Orr EC, Amphlett GW, Foster WB, Coe ML, Knutson GJ, Fass DN, Hewick RM. Molecular cloning of a cDNA encoding human antihemophilic factor. *Nature* 1984; **312**: 342-7.
26. Cripe LD, Moore KD, Kane WH. Structure of the gene for human coagulation factor V. *Biochemistry* 1992; **31**: 3777-85.
27. Ortel TL, Takahashi N, Putnam FW. Structural model of human ceruloplasmin based on internal triplication, hydrophilic/hydrophobic character, and secondary structure of domains. *Proc Natl Acad Sci USA* 1984; **81**: 4761-5.
28. Jenny RJ, Pittman DD, Toole JJ, Kriz RW, Aldape RA, Hewick RM, Kaufman RJ, Mann KG. Complete cDNA and derived amino acid sequence of human factor V. *Proc Natl Acad Sci USA* 1987; **84**: 4846-50.
29. Sadler JE. Biochemistry and genetics of von Willebrand factor. *Annu Rev Biochem* 1998; **67**: 395-424.
30. Shelton-Inloes BB, Titani K, Sadler JE. cDNA sequences for human von Willebrand factor reveal five types of repeated domains and five possible protein sequence polymorphisms. *Biochemistry* 1986; **25**: 3164-71.
31. Gierasch LM. Signal sequences. *Biochemistry* 1989; **28**: 923-30.
32. von Heijne G. The signal peptide. *J Membr Biol* 1990; **115**: 195-201.
33. von Heijne G. Signal sequences. The limits of variation. *J Mol Biol* 1985; **184**: 99-105.
34. Watzke HH, Wallmark A, Hamaguchi N, Giardina P, Stafford DW, High KA. Factor X Santo Domingo. Evidence that the severe clinical phenotype arises from a mutation blocking secretion. *J Clin Invest* 1991; **88**: 1685-9.
35. Racchi M, Watzke HH, High KA, Lively MO. Human coagulation factor X deficiency caused by a mutant signal peptide that blocks cleavage by signal peptidase but not targeting and translocation to the endoplasmic reticulum. *J Biol Chem* 1993; **268**: 5735-40.
36. Daly M, Bruce D, Perry DJ, Price J, Harper PL, O'Meara A, Carrell RW. Antithrombin Dublin (-3 Val---Glu): an N-terminal variant which has an aberrant signal peptidase cleavage site. *FEBS Lett.* 1990; **273**: 87-90.
37. Kemball-Cook G, Tuddenham EG, Wacey AI. The factor VIII Structure and Mutation Resource Site: HAMSTeRS version 4. *Nucleic Acids Res* 1998; **26**: 216-9.
38. Giannelli F, Green PM, Sommer SS, Poon M, Ludwig M, Schwaab R, Reitsma PH, Goossens M, Yoshioka A, Figueiredo MS, Brownlee GG. Haemophilia B: database of point mutations and short additions and deletions—eighth edition. *Nucleic Acids Res* 1998; **26**: 265-8.
39. Lorand L, Jeong JM, Radek JT, Wilson J. Human plasma factor XIII: subunit interactions and activation of zymogen. *Methods Enzymol* 1993; **222**: 22-35.
40. Nickel W. The mystery of nonclassical protein secretion. A current view on cargo proteins and potential export routes. *Eur J Biochem* 2003; **270**: 2109-19.
41. Hemker HC, Veltkamp JJ, Hensen A, Loeliger EA. Nature of prothrombin biosynthesis: Preprothrombinaemia in vitamin K-deficiency. *Nature* 1963; **200**: 589-90.
42. Ganrot PO, Niléhn JE. Plasma prothrombin during treatment with dicumarol. II. Demonstration of an abnormal prothrombin fraction. *Scand J Clin Lab Invest* 1968; **22**: 23-8.
43. Stenflo J, Ganrot P. Vitamin K and the biosynthesis of prothrombin. I. Identification and purification of a dicumarol-induced abnormal prothrombin from bovine plasma. *J Biol Chem* 1972; **247**: 8160-6.
44. Stenflo J, Dahlbäck B. Vitamin K-dependent proteins in blood coagulation. *The Molecular Basis of Blood Disease* (Stamatoyannopoulos G, Majerus PW, Perlmutter RM, Varmus H, eds) W. B. Saunders Company, Philadelphia, 2001; 579-613.

45. Brown MA, Stenflo J. Gla domain. *Handbook of Metalloproteins* (Messerschmidt A, Bode W, Cygler M, eds) John Wiley & Sons, Ltd, Chichester, 2004; **3**: 573-583.
46. Dahlbäck B, Villoutreix BO. Molecular recognition in the protein C anticoagulant pathway. *J Thromb Haemost* 2003; **1**: 1525-34.
47. Esmon CT. The protein C pathway. *Chest* 2003; **124**: 26S-32S.
48. Broze GJ. Protein Z-dependent regulation of coagulation. *Thromb Haemost* 2001; **86**: 8-13.
49. Melaragno MG, Fridell YW, Berk BC. The Gas6/Axl system: a novel regulator of vascular cell function. *Trends Cardiovasc Med* 1999; **9**: 250-3.
50. Kulman JD, Harris JE, Haldeman BA, Davie EW. Primary structure and tissue distribution of two novel proline-rich γ -carboxyglutamic acid proteins. *Proc Natl Acad Sci USA* 1997; **94**: 9058-62.
51. Kulman JD, Harris JE, Xie L, Davie EW. Identification of two novel transmembrane γ -carboxyglutamic acid proteins expressed broadly in fetal and adult tissues. *Proc Natl Acad Sci USA* 2001; **98**: 1370-5.
52. Hoang QQ, Sicheri F, Howard AJ, Yang DS. Bone recognition mechanism of porcine osteocalcin from crystal structure. *Nature* 2003; **425**: 977-80.
53. Luo G, Ducy P, McKee MD, Pinero GJ, Loyer E, Behringer RR, Karsenty G. Spontaneous calcification of arteries and cartilage in mice lacking matrix Gla protein. *Nature* 1997; **386**: 78-81.
54. Wang CP, Yagi K, Lin PJ, Jin DY, Makabe KW, Stafford DW. Identification of a gene encoding a typical γ -carboxyglutamic acid domain in the tunicate *Halocynthia roretzi*. *J Thromb Haemost* 2003; **1**: 118-23.
55. Jiang Y, Doolittle RF. The evolution of vertebrate blood coagulation as viewed from a comparison of puffer fish and sea squirt genomes. *Proc Natl Acad Sci USA* 2003; **100**: 7527-32.
56. Olivera BM. *Conus* venom peptides, receptor and ion channel targets, and drug design: 50 million years of neuropharmacology. *Mol Biol Cell* 1997; **8**: 2101-9.
57. Li T, Yang CT, Jin D, Stafford DW. Identification of a *Drosophila* vitamin K-dependent γ -glutamyl carboxylase. *J Biol Chem* 2000; **275**: 18291-6.
58. Furie B, Furie BC. Molecular basis of vitamin K-dependent γ -carboxylation. *Blood* 1990; **75**: 1753-62.
59. Wu SM, Cheung WF, Frazier D, Stafford DW. Cloning and expression of the cDNA for human γ -glutamyl carboxylase. *Science* 1991; **254**: 1634-6.
60. Bristol JA, Ratcliffe JV, Roth DA, Jacobs MA, Furie BC, Furie B. Biosynthesis of prothrombin: intracellular localization of the vitamin K-dependent carboxylase and the sites of γ -carboxylation. *Blood* 1996; **88**: 2585-93.
61. Presnell SR, Stafford DW. The vitamin K-dependent carboxylase. *Thromb Haemost* 2002; **87**: 937-46.
62. Rost S, Fregin A, Ivaskevicius V, Conzelmann E, Hörtnagel K, Pelz HJ, Lappégard K, Seifried E, Scharrer I, Tuddenham EG, Müller CR, Strom TM, Oldenburg J. Mutations in *VKORC1* cause warfarin resistance and multiple coagulation factor deficiency type 2. *Nature* 2004; **427**: 537-41.
63. Li T, Chang C-Y, Jin D-Y, Lin P-J, Khvorova A, Stafford DW. Identification of the gene for vitamin K epoxide reductase. *Nature* 2004; **427**: 541-4.
64. Kurachi K, Davie EW. Isolation and characterization of a cDNA coding for human factor IX. *Proc Natl Acad Sci USA* 1982; **79**: 6461-4.
65. Diguil DL, Rabiet MJ, Furie BC, Liebman HA, Furie B. Molecular basis of hemophilia B: a defective enzyme due to an unprocessed propeptide is caused by a point mutation in the factor IX precursor. *Proc Natl Acad Sci USA*. 1986; **83**: 5803-7.

66. Knobloch JE, Suttie JW. Vitamin K-dependent carboxylase. Control of enzyme activity by the "propeptide" region of factor X. *J Biol Chem* 1987; **262**: 15334-7.
67. Stanley TB, Wu S-M, Houben RJTJ, Mutucumarana VP, Stafford DW. Role of the propeptide and γ -glutamic acid domain of factor IX for in vitro carboxylation by the vitamin K-dependent carboxylase. *Biochemistry* 1998; **37**: 13262-8.
68. Morris DP, Stevens RD, Wright DJ, Stafford DW. Processive post-translational modification. Vitamin K-dependent carboxylation of a peptide substrate. *J Biol Chem* 1995; **270**: 30491-8.
69. Stenina O, Pudota BN, McNally BA, Hommema EL, Berkner KL. Tethered processivity of the vitamin K-dependent carboxylase: factor IX is efficiently modified in a mechanism which distinguishes Glu's from Glu's and which accounts for comprehensive carboxylation in vivo. *Biochemistry* 2001; **40**: 10301-9.
70. Soriano-Garcia M, Padmanabhan K, de Vos AM, Tulinsky A. The Ca^{2+} ion and membrane binding structure of the Gla domain of Ca^{2+} -prothrombin fragment 1. *Biochemistry* 1992; **31**: 2554-66.
71. Oganesyanyan V, Oganesyanyan N, Terzyan S, Qu D, Dauter Z, Esmon NL, Esmon CT. The crystal structure of the endothelial protein C receptor and a bound phospholipid. *J Biol Chem* 2002; **277**: 24851-4.
72. Welsh DJ, Nelsestuen GL. Amino-terminal alanine functions in a calcium-specific process essential for membrane binding by prothrombin fragment 1. *Biochemistry* 1988; **27**: 4939-45.
73. Tulinsky A, Park CH, Skrzypczak-Jankun E. Structure of prothrombin fragment 1 refined at 2.8 Å resolution. *J Mol Biol* 1988; **202**: 885-901.
74. Sunnerhagen M, Forsén S, Hoffrén AM, Drakenberg T, Teleman O, Stenflo J. Structure of the Ca^{2+} -free Gla domain sheds light on membrane binding of blood coagulation proteins. *Nat Struct Biol* 1995; **2**: 504-9.
75. Freedman SJ, Furie BC, Furie B, Baleja JD. Structure of the calcium ion-bound γ -carboxyglutamic acid-rich domain of factor IX. *Biochemistry* 1995; **34**: 12126-37.
76. Jackson CM. Calcium ion binding to γ -carboxyglutamic acid-containing proteins from the blood clotting system: What we still don't understand. *Current Advances in Vitamin K Research* (Suttie JW, ed) Elsevier, New York, 1988; 305-24.
77. Nelsestuen GL. Role of γ -carboxyglutamic acid. An unusual protein transition required for the calcium-dependent binding of prothrombin to phospholipid. *J Biol Chem* 1976; **251**: 5648-56.
78. Bloom JW, Mann KG. Metal ion induced conformational transitions of prothrombin and prothrombin fragment 1. *Biochemistry* 1978; **17**: 4430-8.
79. Persson E, Björk I, Stenflo J. Protein structural requirements for Ca^{2+} -binding to the light chain of factor X. Studies using isolated intact fragments containing the γ -carboxyglutamic acid region and/or the epidermal growth factor-like domains. *J Biol Chem* 1991; **266**: 2444-52.
80. Mann KG, Nesheim ME, Church WR, Haley P, Krishnaswamy S. Surface-dependent reactions of the vitamin K-dependent enzyme complexes. *Blood* 1990; **76**: 1-16.
81. Pei G, Powers DD, Lentz BR. Specific contribution of different phospholipid surfaces to the activation of prothrombin by the fully assembled prothrombinase. *J Biol Chem* 1993; **268**: 3226-33.
82. Gerads I, Govers-Riemslog JW, Tans G, Zwaal RF, Rosing J. Prothrombin activation on membranes with anionic lipids containing phosphate, sulfate, and/or carboxyl groups. *Biochemistry* 1990; **29**: 7967-74.

83. Freedman SJ, Blostein MD, Baleja JD, Jacobs M, Furie BC, Furie B. Identification of the phospholipid binding site in the vitamin K-dependent blood coagulation protein factor IX. *J Biol Chem* 1996; **271**: 16227-36.
84. Nelsestuen GL, Kisiel W, Di Scipio RG. Interaction of vitamin K dependent proteins with membranes. *Biochemistry* 1978; **17**: 2134-8.
85. Huang M, Rigby AC, Morelli X, Grant MA, Huang G, Furie B, Seaton B, Furie BC. Structural basis of membrane binding by Gla domains of vitamin K-dependent proteins. *Nat Struct Biol* 2003; **10**: 751-6.
86. Malhotra OP, Nesheim ME, Mann KG. The kinetics of activation of normal and γ -carboxyglutamic acid-deficient prothrombins. *J Biol Chem* 1985; **260**: 279-87.
87. Stenflo J. Structure-function relationships of epidermal growth factor modules in vitamin K-dependent clotting factors. *Blood* 1991; **78**: 1637-51.
88. Boswell EJ, Kurinawan ND, Downing AK. Calcium-binding EGF-like domains. *Handbook of Metalloproteins* (Messerschmidt A, Bode W, Cygler M, eds) John Wiley & Sons, Ltd, Chichester 2004; **3**: 1-18.
89. Fernlund P, Stenflo J. β -Hydroxyaspartic acid in vitamin K-dependent proteins. *J Biol Chem* 1983; **258**: 12509-12.
90. Stenflo J, Holme E, Lindstedt S, Chandramouli N, Huang LH, Tam JP, Merrifield RB. Hydroxylation of aspartic acid in domains homologous to the epidermal growth factor precursor is catalyzed by a 2-oxoglutarate-dependent dioxygenase. *Proc Natl Acad Sci USA* 1989; **86**: 444-7.
91. Jia S, VanDusen WJ, Diehl RE, Kohl NE, Dixon RA, Elliston KO, Stern AM, Friedman PA. cDNA cloning and expression of bovine aspartyl (asparaginy) β -hydroxylase. *J Biol Chem* 1992; **267**: 14322-27.
92. Stenflo J, Fernlund P. β -hydroxyaspartic acid in vitamin K-dependent plasma proteins from scorbutic and warfarin-treated guinea pigs. *FEBS Lett.* 1984; **168**: 287-92.
93. Dinchuk JE, Focht RJ, Kelley JA, Henderson NL, Zolotarjova NI, Wynn R, Neff NT, Link J, Huber RM, Burn TC, Rupar MJ, Cunningham MR, Selling BH, Ma J, Stern AA, Hollis GF, Stein RB, Friedman PA. Absence of post-translational aspartyl-hydroxylation of epidermal growth factor domains in mice leads to developmental defects and an increased incidence of intestinal neoplasia. *J Biol Chem* 2002; **277**: 12970-7.
94. Przysiecki C, Staggers JE, Ramjit HG, Musson DG, Stern AM, Bennett CD, Friedman PA. Occurrence of β -hydroxylated asparagine residues in non-vitamin K-dependent proteins containing epidermal growth factor-like domains. *Proc Natl Acad Sci USA* 1987; **84**: 7856-60.
95. Öhlin AK, Stenflo J. Calcium-dependent interaction between the epidermal growth factor precursor-like region of human protein C and a monoclonal antibody. *J Biol Chem* 1987; **262**: 13798-804.
96. Öhlin AK, Linse S, Stenflo J. Calcium binding to the epidermal growth factor homology region of bovine protein C. *J Biol Chem* 1988; **263**: 7411-7.
97. Handford PA, Mayhew M, Baron M, Winship PR, Campbell ID, Brownlee GG. Key residues involved in calcium-binding motifs in EGF-like domains. *Nature* 1991; **351**: 164-7.
98. Selander-Sunnerhagen M, Ullner M, Persson E, Telemann O, Stenflo J, Drakenberg T. How an epidermal growth factor (EGF)-like domain binds calcium. High resolution NMR structure of the calcium form of the NH₂-terminal EGF-like domain in coagulation factor X. *J Biol Chem* 1992; **267**: 19642-9.
99. Rao Z, Handford P, Mayhew M, Knott V, Brownlee GG, Stuart D. The structure of a Ca²⁺-binding epidermal growth factor-like domain: its role in protein-protein interactions. *Cell* 1995; **82**: 131-41.

100. Sunnerhagen MS, Persson E, Dahlqvist I, Drakenberg T, Stenflo J, Mayhew M, Robin M, Handford P, Tilley JW, Campbell ID, Brownlee GG. The effect of aspartate hydroxylation on calcium binding to epidermal growth factor-like modules in coagulation factors IX and X. *J Biol Chem* 1993; **268**: 23339-44.
101. Handford PA, Baron M, Mayhew M, Willis A, Beesley T, Brownlee GG, Campbell ID. The first EGF-like domain from human factor IX contains a high-affinity calcium binding site. *EMBO J* 1990; **9**: 475-80.
102. Nelson RM, VanDusen WJ, Friedman PA, Long GL. β -Hydroxyaspartic acid and β -hydroxyasparagine residues in recombinant human protein S are not required for anticoagulant cofactor activity or for binding to C4b-binding protein. *J Biol Chem* 1991; **266**: 20586-9.
103. Lando D, Peet DJ, Whelan DA, Gorman JJ, Whitelaw ML. Asparagine hydroxylation of the HIF transactivation domain: a hypoxic switch. *Science* 2002; **295**: 858-61.
104. McNeill LA, Hewitson KS, Claridge TD, Seibel JF, Horsfall LE, Schofield CJ. Hypoxia-inducible factor asparaginyl hydroxylase (FIH-1) catalyses hydroxylation at the β -carbon of asparagine-803. *Biochem J*. 2002; **367**: 571-5.
105. Hurlley SM, Helenius A. Protein oligomerization in the endoplasmatic reticulum. *Annu Rev Cell Biol* 1989; **5**: 277-307.
106. Helenius A, Aebi M. Roles of N-linked glycans in the endoplasmatic reticulum. *Annu Rev Biochem* 2004; **73**: 1019-49.
107. Rademacher TW, Parekh RB, Dwek RA. Glycobiology. *Annu Rev Biochem* 1988; **57**: 785-838.
108. Drickhamer K. Clearing up glycoprotein hormones. *Cell* 1991; **67**: 1029-32.
109. Rasmussen J. Effect of glycosylation on protein function. *Curr Opinion Struct Biol* 1992; **2**: 682-6.
110. Kasturi L, Eshleman JR, Wunner WH, Shakin-Eshleman SH. The hydroxy amino acid in an Asn-X-Ser/Thr sequon can influence N-linked core glycosylation efficiency and the level of expression of a cell surface glycoprotein. *J Biol Chem* 1995; **270**: 14756-14761.
111. Beeley JG. Peptide chain conformation and the glycosylation of glycoproteins. *Biochem Biophys Res Commun* 1977 ; **76**: 1051-5.
112. Stenflo J, Fernlund P. Amino acid sequence of the heavy chain of bovine protein C. *J Biol Chem* 1982; **257**: 12180-90.
113. Foster D, Davie EW. Characterization of a cDNA coding for human protein C. *Proc Natl Acad Sci USA* 1984; **81**: 4766-70.
114. Titani K, Kumar S, Takio K, Ericsson LH, Wade RD, Ashida K, Walsh KA, Chopek MW, Sadler JE, Fujikawa K. Amino acid sequence of human von Willebrand factor. *Biochemistry* 1986; **25**: 3171-84.
115. Van den Steen P, Rudd PM, Dwek RA, Opdenakker G. Concepts and principles of O-linked glycosylation. *Crit Rev Biochem Mol Biol* 1998; **33**: 151-208.
116. Harris RJ, Spellman MW. O-linked fucose and other post-translational modifications unique to EGF modules. *Glycobiology* 1993; **3**: 219-24.
117. Harris RJ, van Halbeek H, Glushka J, Basa LJ, Ling VT, Smith KJ, Spellman MW. Identification and structural analysis of the tetrasaccharide NeuAc α (2 \rightarrow 6)Gal β (1 \rightarrow 4)GlcNAc β (1 \rightarrow 3)Fuc α 1 \rightarrow O-linked to serine 61 of human factor IX. *Biochemistry* 1993; **32**: 6539-47.
118. Kane WH, Davie EW. Blood coagulation factors V and VIII: structural and functional similarities and their relationship to hemorrhagic and thrombotic disorders. *Blood* 1988; **71**: 539-55.

119. Dorner AJ, Bole DG, Kaufman RJ. The relationship of N-linked glycosylation and heavy chain-binding protein association with the secretion of glycoproteins. *J Cell Biol* 1987; **105**: 2665-74.
120. Pittman DD, Tomkinson KN, Kaufman RJ. Post-translational requirements for functional factor V and factor VIII secretion in mammalian cells. *J Biol Chem* 1994; **269**: 17329-37.
121. Pipe SW, Morris JA, Shah J, Kaufman RJ. Different interaction of coagulation factor VIII and factor V with protein chaperones calnexin and calreticulin. *J Biol Chem* 1998; **273**: 8537-44.
122. Nichols WC, Seligsohn U, Zivelin A, Terry VH, Hertel CE, Wheatley MA, Moussalli MJ, Hauri H-P, Ciavarella N, Kaufan RJ, Ginsburg D. Mutations in the ER-Golgi intermediate compartment protein ERGIC-53 cause combined deficiency of coagulation factors V and VIII. *Cell* 1998; **93**: 61-70.
123. Cunningham MA, Pipe SW, Zhang B, Hauri H-P, Ginsburg D, Kaufman RJ. LMAN1 is a molecular chaperone for the secretion of coagulation factor VIII. *J Thromb Haemost* 2003; **1**: 2360-7.
124. Fernandez JA, Hackeng TM, Kojima K, Griffin JH. The carbohydrate moiety of factor V modulates inactivation by activated protein C. *Blood* 1997; **89**: 4348-54.
125. Silveira JR, Kalafatis M, Tracy PB. Carbohydrate moieties on the procofactor factor V, but not the derived cofactor factor Va, regulate its inactivation by activated protein C. *Biochemistry* 2002; **41**: 1672-80.
126. Rosing J, Bakker HM, Thomassen MC, Hemker HC, Tans G. Characterization of two forms of human factor Va with different cofactor activities. *J Biol Chem* 1993; **268**: 21130-6.
127. Nicolaes GA, Villoutreix BO, Dahlbäck B. Partial glycosylation of Asn2181 in human factor V as a cause of molecular and functional heterogeneity. Modulation of glycosylation efficiency by mutagenesis of the consensus sequence for N-linked glycosylation. *Biochemistry*. 1999; **38**: 13584-91.
128. Kim SW, Ortel TL, Quinn-Allen MA, Yoo L, Worfolk L, Zhai X, Lentz BR, Kane WH. Partial glycosylation at asparagine-2181 of the second C-type domain of human factor V modulates assembly of the prothrombinase complex. *Biochemistry* 1999; **38**: 11448-54.
129. Mumford AD, McVey JH, Morse CV, Gomez K, Steen M, Norstrom EA, Tuddenham EGD, Dahlbäck B, Bolton-Maggs PHB. Factor V139T: a novel mutation associated with thrombosis and resistance to activated protein C. *Br J Haematol* 2003; **123**: 496-501.
130. Steen M, Norstrom EA, Tholander A-L, Bolton-Maggs PHB, Mumford A, JH. McVey, Tuddenham EGD, Dahlbäck B. Functional characterization of factor V-Ile359Thr: a novel mutation associated with thrombosis. *Blood* 2004; **103**: 3381-7.
131. Aly AM, Higuchi M, Kasper CK, Kazazian HH Jr, Antonarakis SE, Hoyer LW. Hemophilia A due to mutations that create new N-glycosylation sites. *Proc Natl Acad Sci USA* 1992; **89**: 4933-7.
132. Matsui T, Titani K, Mizuochi T. Structures of the asparagine-linked oligosaccharide chains of human von Willebrand factor. Occurrence of blood group A, B, and H(O) structures. *J Biol Chem* 1992; **267**: 8723-31.
133. Carew JA, Browning PJ, Lynch DC. Sulfation of von Willebrand factor. *Blood* 1990; **76**: 2530-9.
134. Wagner DD, Mayadas T, Marder VJ. Initial glycosylation and acidic pH in the Golgi apparatus are required for multimerization of von Willebrand factor. *J Cell Biol* 1986; **102**: 1320-4.
135. Martin DM, Boys CW, Ruf W. Tissue factor: molecular recognition and cofactor function. *FASEB J* 1995; **9**: 852-9.

136. Nishimura H, Takao T, Hase S, Shimonishi Y, Iwanaga S. Human factor IX has a tetrasaccharide O-glycosidically linked to serine 61 through the fucose residue. *J Biol Chem* 1992; **267**: 17520-5.
137. Moloney DJ, Panin VM, Johnston SH, Chen J, Shao L, Wilson R, Wang Y, Stanley P, Irvine KD, Haltiwanger RS, Vogt TF. Fringe is a glycosyltransferase that modifies Notch. *Nature* 2000; **406**: 369-75.
138. Chen J, Moloney DJ, Stanley P. Fringe modulation of Jagged1-induced Notch signaling requires the action of β 4galactosyltransferase-1. *Proc Natl Acad Sci USA* 2001; **98**: 13716-21.
139. Kao YH, Lee GF, Wang Y, Starovasnik MA, Kelley RF, Spellman MW, Lerner L. The effect of O-fucosylation on the first EGF-like domain from human blood coagulation factor VII. *Biochemistry* 1999; **38**: 7097-110.
140. Nishimura H, Kawabata S, Kisiel W, Hase S, Ikenaka T, Takao T, Shimonishi Y, Iwanaga S. Identification of a disaccharide (Xyl-Glc) and a trisaccharide (Xyl₂-Glc) O-glycosidically linked to a serine residue in the first epidermal growth factor-like domain of human factors VII and IX and protein Z and bovine protein Z. *J Biol Chem* 1989; **264**: 20320-5.
141. Bond MD, Huberty MC, Jankowski MA, Vath JE, Strang A-M, Scoble HA. Identification of O-glycosylation, sulfation and phosphorylation sites in the activation peptide of human plasma factor IX. *Blood* 1994; **84** (Suppl I): 531a.
142. Agarwala KL, Kawabata S, Takao T, Murata H, Shimonishi Y, Nishimura H, Iwanaga. Activation peptide of human factor IX has oligosaccharides O-glycosidically linked to threonine residues at 159 and 169. *Biochemistry* 1994; **33**: 5167-71.
143. Di Scipio RG, Hermodson MA, Davie EW. Activation of human factor X (Stuart factor) by a protease from Russell's viper venom. *Biochemistry* 1977; **16**: 5253-60.
144. Jackson CM. Factor X. *Prog Hemost Thromb* 1984; **7**: 55-109.
145. Inoue K, Morita T. Identification of O-linked oligosaccharide chains in the activation peptides of blood coagulation factor X. The role of the carbohydrate moieties in the activation of factor X. *Eur J Biochem* 1993; **218**: 153-63.
146. Sinha U, Wolf DL. Carbohydrate residues modulate the activation of coagulation factor X. *J Biol Chem* 1993; **268**: 3048-51.
147. Iino M, Takeya H, Nishioka J, Nakagaki T, Tamura K, Suzuki K. The role of human factor X activation peptide in activation of factor X by factor IXa. *J Biochem (Tokyo)* 1994; **116**: 335-40.
148. Bharadwaj D, Harris RJ, Kisiel W, Smith KJ. Enzymatic removal of sialic acid from human factor IX and factor X has no effect on their coagulant activity. *J Biol Chem* 1995; **270**: 6537-42.
149. Baugh RJ, Krishnaswamy S. Role of the activation peptide domain in human factor X activation by the extrinsic Xase complex. *J Biol Chem* 1996; **271**: 16126-34.
150. Degen SJ. The prothrombin gene and its liver-specific expression. *Semin Thromb Hemost* 1992; **18**: 230-42.
151. Wu W, Suttie JW. N-glycosylation contributes to the intracellular stability of prothrombin precursors in the endoplasmic reticulum. *Thromb Res* 1999; **96**: 91-8.
152. Foster DC, Yoshitake S, Davie EW. The nucleotide sequence of the gene for human protein C. *Proc Natl Acad Sci USA* 1985; **82**: 4673-7.
153. Grinnell BW, Walls JD, Gerlitz B. Glycosylation of human protein C affects its secretion, processing, functional activities, and activation by thrombin. *J Biol Chem* 1991; **266**: 9778-85.

154. McClure DB, Walls JD, Grinnell BW. Post-translational processing events in the secretion pathway of human protein C, a complex vitamin K-dependent antithrombotic factor. *J Biol Chem* 1992; **267**: 19710-7.
155. Lu D, Xie R-L, Rydzewski A, Long GL. The effect on N-linked glycosylation on molecular weight, thrombin cleavage, and functional activity of human protein S. *Thromb Haemost* 1997; **77**: 1156-63.
156. Dahlbäck B, Stenflo J. High molecular weight complex in human plasma between vitamin K-dependent protein S and complement component C4b-binding protein. *Proc Natl Acad Sci USA* 1981; **78**: 2512-6.
157. Dahlbäck B. Inhibition of protein C cofactor function of human and bovine protein S by C4b-binding protein. *J Biol Chem* 1986; **261**: 12022-7.
158. Giri TK, Linse S, García de Frutos P, Yamazaki T, Villoutreix BO, Dahlbäck B. Structural requirements of anticoagulant protein S for its binding to the complement regulator C4b-binding protein. *J Biol Chem* 2002; **277**: 15099-106.
159. Bertina RM, Ploos van Amstel HK, van Wijngaarden A, Coenen J, Leemhuis MP, Deutz-Terlouw PP, van der Linden IK, Reitsma PH. Heerlen polymorphism of protein S, an immunologic polymorphism due to dimorphism of residue 460. *Blood* 1990; **76**: 538-48.
160. Giri TK, Yamazaki T, Sala N, Dahlbäck B, García de Frutos P. Deficient APC-cofactor activity of protein S Heerlen in degradation of factor Va Leiden: a possible mechanism of synergism between thrombophilic risk factors. *Blood* 2000; **96**: 523-31.
161. Franzen LE, Svensson S, Larm O. Structural studies on the carbohydrate portion of human antithrombin III. *J Biol Chem* 1980; **255**: 5090-3.
162. Peterson CB, Blackburn MN. Isolation and characterization of an antithrombin III variant with reduced carbohydrate content and enhanced heparin binding. *J Biol Chem* 1985; **260**: 610-5.
163. Brennan SO, George PM, Jordan RE. Physiological variant of antithrombin-III lacks carbohydrate sidechain at Asn 135. *FEBS Lett* 1987 ; **219**: 431-6.
164. Picard V, Ersdal-Badju E, Bock SC. Partial glycosylation of antithrombin III asparagine-135 is caused by the serine in the third position of its N-glycosylation consensus sequence and is responsible for production of the β -antithrombin III isoform with enhanced heparin affinity. *Biochemistry* 1995; **34**: 8433-40.
165. Turko IV, Fan B, Gettins PG. Carbohydrate isoforms of antithrombin variant N135Q with different heparin affinities. *FEBS Lett* 1993; **335**: 9-12.
166. Witmer MR, Hatton MW. Antithrombin III- β associates more readily than antithrombin III- α with uninjured and de-endothelialized aortic wall in vitro and in vivo. *Arterioscler Thromb* 1991; **11**: 530-9.
167. Turk B, Brieditis I, Bock SC, Olson ST, Björk I. The oligosaccharide side chain on Asn-135 of α -antithrombin, absent in β -antithrombin, decreases the heparin affinity of the inhibitor by affecting the heparin-induced conformational change. *Biochemistry* 1997; **36**: 6682-91.
168. Olson ST, Frances-Chmura AM, Swanson R, Björk I, Zettlmeissl G. Effect of individual carbohydrate chains of recombinant antithrombin on heparin affinity and on the generation of glycoforms differing in heparin affinity. *Arch Biochem Biophys* 1997; **341**: 212-21.
169. Fujita M, Izutani W, Takahashi K, Nishizawa K, Shirono H, Koga J. Role of each Asn-linked glycan in the anticoagulant activity of human protein C inhibitor. *Thromb Res* 2002; **105**: 95-102.
170. Bayston TA, Tripodi A, Mannucci PM, Thompson E, Ireland H, Fitches AC, Hananeia L, Olds RJ, Lane DA. Familial overexpression of β antithrombin caused by an Asn135Thr substitution. *Blood* 1999; **93**: 4242-7.

171. Brennan SO, Borg JY, George PM, Soria C, Soria J, Caen J, Carrell RW. New carbohydrate site in mutant antithrombin (7 Ile----Asn) with decreased heparin affinity. *FEBS Lett* 1988; **237**: 118-22.
172. Fitches AC, Lewandowski K, Olds RJ. Creation of an additional glycosylation site as a mechanism for type I antithrombin deficiency. *Thromb Haemost* 2001; **86**: 1023-7.
173. Björk I, Ylinenjarvi K, Olson ST, Hermentin P, Conradt HS, Zettlmeissl G. Decreased affinity of recombinant antithrombin for heparin due to increased glycosylation. *Biochem J* 1992; **286**: 793-800.
174. Zettlmeissl G, Conradt HS, Nimtz M, Karges HE. Characterization of recombinant human antithrombin III synthesized in Chinese hamster ovary cells. *J Biol Chem* 1989; **264**: 21153-9.
175. Weiler H, Isermann BH. Thrombomodulin. *J Thromb Haemost* 2003; **1**: 1515-24.
176. Lee RW, Huttner WB. Tyrosine-O-sulfated proteins of PC12 pheochromocytoma cells and their sulfation by a tyrosylprotein sulfotransferase. *J Biol Chem* 1983; **258**: 11326-34.
177. Hortin GL. Sulfation of tyrosine residues in coagulation factor V. *Blood* 1990; **76**: 946-52.
178. Leyte A, van Schijndel HB, Niehrs C, Huttner WB, Verbeet MP, Mertens K, van Mourik JA. Sulfation of Tyr1680 of human blood coagulation factor VIII is essential for the interaction of factor VIII with von Willebrand factor. *J Biol Chem* 1991; **266**: 740-6.
179. Mikkelsen J, Thomsen J, Ezban M. Heterogeneity in the tyrosine sulfation of Chinese hamster ovary cell produced recombinant FVIII. *Biochemistry* 1991; **30**: 1533-7.
180. White GC 2nd, Beebe A, Nielsen B. Recombinant factor IX. *Thromb Haemost* 1997; **78**: 261-5.
181. Pittman DD, Tomkinson KN, Michnick D, Selighsohn U, Kaufman RJ. Posttranslational sulfation of factor V is required for efficient thrombin cleavage and activation and for full procoagulant activity. *Biochemistry* 1994; **33**: 6952-9.
182. Pittman DD, Wang JH, Kaufman RJ. Identification and functional importance of tyrosine sulfate residues within recombinant factor VIII. *Biochemistry* 1992; **31**: 3315-25.
183. Higuchi M, Wong C, Kochhan L, Olek K, Aronis S, Kasper CK, Kazazian HH Jr, Antonarakis SE. Characterization of mutations in the factor VIII gene by direct sequencing of amplified genomic DNA. *Genomics* 1990; **6**: 65-71.
184. Michnick DA, Pittman DD, Wise RJ, Kaufman RJ. Identification of individual tyrosine sulfation sites within factor VIII required for optimal activity and efficient thrombin cleavage. *J Biol Chem* 1994; **269**: 20095-102.
185. Mumford AD, Laffan M, O'Donnell J, McVey JH, Johnson DJ, Manning RA, Kembell-Cook G. A Tyr346-->Cys substitution in the interdomain acidic region a1 of factor VIII in an individual with factor VIII:C assay discrepancy. *Br J Haematol* 2002; **118**: 589-94.
186. Abe K, Sakurada K, Tanaka M, Uehara Y, Matsuno K, Miyazaki T, Katoh N. Phosphorylation of coagulation factor II by phospholipid/Ca(2+)-dependent protein kinase (protein kinase C). *Biochem Biophys Res Commun* 1991; **176**: 1123-9.
187. Kalafatis M, Rand MD, Jenny RJ, Ehrlich YH, Mann KG. Phosphorylation of factor Va and factor VIIIa by activated platelets. *Blood* 1993; **81**: 704-19.
188. Rand MD, Kalafatis M, Mann KG. Platelet coagulation factor Va: the major secretory platelet phosphoprotein. *Blood* 1994; **83**: 2180-90.
189. Kalafatis M. Identification and partial characterization of factor Va heavy chain kinase from human platelets. *J Biol Chem* 1998; **273**: 8459-66.
190. Wise RJ, Barr PJ, Wong PA, Kiefer MC, Brake AJ, Kaufman RJ. Expression of a human proprotein processing enzyme: correct cleavage of the von Willebrand factor precursor at a paired basic amino acid site. *Proc Natl Acad Sci USA* 1990; **87**: 9378-82.

191. Wasley LC, Rehemtulla A, Bristol JA, Kaufman RJ. PACE/furin can process the vitamin K-dependent pro-factor IX precursor within the secretory pathway. *J Biol Chem* 1993; **268**: 8458-65.
192. Drews R, Paleyanda RK, Lee TK, Chang RR, Rehemtulla A, Kaufman RJ, Drohan WN, Lubon H. Proteolytic maturation of protein C upon engineering the mouse mammary gland to express furin. *Proc Natl Acad Sci USA* 1995; **92**: 10462-6.
193. Busby SJ, Berkner KL, Halfpap LM, Gambie JE, Kumar AA. Alteration of propeptide sequence impairs biological activity of human factor VII. *Current Advances in Vitamin K Research* (Suttie JW, ed) Elsevier Science, New York, 1988; 173-181.
194. Gandrille S, Borgel D, Eschwege-Gufflet V, Aillaud M, Dreyfus M, Matheron C, Gaussem P, Abgrall JF, Jude B, Sie P, Toulon P, Aiach M. Identification of 15 different candidate causal point mutations and three polymorphisms in 19 patients with protein S deficiency using a scanning method for the analysis of the protein S active gene. *Blood* 1995; **85**: 130-8.
195. Miyata T, Zheng YZ, Sakata T, Kato H. Protein C Osaka 10 with aberrant propeptide processing: loss of anticoagulant activity due to an amino acid substitution in the protein C precursor. *Thromb Haemost* 1995; **74**: 1003-8.
196. Ware J, Diuguid DL, Liebman HA, Rabiet MJ, Kasper CK, Furie BC, Furie B, Stafford DW. Factor IX San Dimas. Substitution of glutamine for Arg-4 in the propeptide leads to incomplete γ -carboxylation and altered phospholipid binding properties. *J Biol Chem* 1989; **264**: 11401-6.
197. Diuguid DL, Rabiet MJ, Furie BC, Liebman HA, Furie B. Molecular basis of hemophilia B: a defective enzyme due to an unprocessed propeptide is caused by a point mutation in the factor IX precursor. *Proc Natl Acad Sci USA* 1986; **83**: 5803-7.
198. Verweij CL, Hart M, Pannekoek H. Expression of variant von Willebrand factor (vWF) cDNA in heterologous cells: requirement of the pro-polypeptide in vWF multimer formation. *EMBO J* 1987; **6**: 2885-90.
199. Wise RJ, Pittman DD, Handin RI, Kaufman RJ, Orkin SH. The propeptide of von Willebrand factor independently mediates the assembly of von Willebrand multimers. *Cell* 1988; **52**: 229-36.
200. Bendetowicz AV, Morris JA, Wise RJ, Gilbert GE, Kaufman RJ. Binding of factor VIII to von Willebrand factor is enabled by cleavage of the von Willebrand factor propeptide and enhanced by formation of disulfide-linked multimers. *Blood* 1998; **92**: 529-38.

Legends to figures

Fig. 1. Schematic representation of vitamin K-dependent plasma coagulation proteins. Locations of post-translational modifications (identified in the key) are denoted. Homologous domains are similarly coloured. Thin arrows indicate proteolytic cleavage sites associated with zymogen activation. Thick arrowheads show proteolytic cleavage sites that are associated with processing in the ER. The disulfide bonds connecting the heavy and light chains are shown. The brown box represents the thrombin-sensitive region of protein S (between the Gla and EGF domain). Gla, γ -carboxyglutamic acid domain; EGF, epidermal growth factor-like domain; KR, kringle domain; LG, laminin G-like domain; SHBG, sex hormone-binding globulin-like domain; TSR, thrombin sensitive domain; SERINE PROTEASE*, serine protease domain that is not catalytically active.

Fig. 2. Structural organization and activation of the plasma cofactor proteins factor V/Va (A) and factor VIII/VIIIa (B). The cofactors contain homologous A and C domains (shown in green and red, respectively), whereas the B domains (shown in grey) are structurally divergent. The structures of the activated cofactors (Va and VIIIa) correspond to those obtained after cleavage of the procofactors by thrombin at the positions indicated by arrows. The subunits of factor Va, a heterodimer, and factor VIIIa, a heterotrimer, are held together by non-covalent interactions in a Ca^{2+} -dependent manner (represented by dashed lines). The location of post-translational modifications are depicted and identified in the key. *, Partial glycosylation at this site (Asn2181) accounts for the two isoforms factor Va1 and factor Va2 (see text).

Fig. 3. Domain structure of human von Willebrand factor. The sites of post-translational modifications are shown in the mature subunit and can be identified in the key. (The three potential N-glycosylation sites at Asn99, Asn156, and Asn211 in the propeptide are not shown). Disulfide-linked dimeric building blocks are formed in the ER from pairs of pro-von Willebrand factor subunits. These dimers are linked through disulfide bonds at their N-termini and assembled into large multimers in the Golgi apparatus before the propeptide is cleaved. *, The oligosaccharides at one or both of these sites (Asn384 and Asn468) are sulfated.

Fig. 4. (A) Amino acid sequences in the Gla domains of human vitamin K-dependent plasma proteins. Numbers are based on human factor VII. Amino acid residues that are identical in at least four of the proteins are marked in yellow. γ indicates the γ -carboxyglutamic acid

residues. Residues that form the ω -loop, the disulfide loop, and the hydrophobic stack region are marked. (B) Post-translational γ -carboxylation of a glutamyl residue to a γ -carboxyglutamyl residue by γ -glutamyl carboxylase.

Fig. 5. Stereoview of the Ca^{2+} -bound Gla domain of bovine prothrombin. The side chains of Phe5, Leu6, and Val9 (of the N-terminal ω -loop) that interact with the phospholipid membrane are depicted in violet at the bottom of the figure. The Ca^{2+} ions (numbered 1–7) are depicted as red spheres and the side chains of the Gla residues are shown in light blue. The side chains of Phe41, Trp42, and Tyr45 in the hydrophobic stack region are shown at the top of the figure in dark blue.

Fig. 6. (A) Schematic model of the four EGF-like domains in human protein S. The hydroxylated Asp and Asn residues are shown in yellow. (B) Post-translational hydroxylation of an aspartyl residue by aspartyl- β -hydroxylase to form *erythro*- β -hydroxyaspartic acid.

Fig. 7. Schematic representation of the Ca^{2+} -binding EGF4 domain from human protein S. The Ca^{2+} ion is depicted as a grey sphere and the Ca^{2+} -liganding amino acids are identified.

Table 1. Sites of post-translational modifications of coagulation factor molecules

Protein	Post-translational modification
Factor V	<i>N-glycosylation</i> : Asn23, Asn27, Asn211, Asn269, Asn354, Asn432, Asn440, Asn526, Asn639, Asn713, Asn724, Asn732, Asn748, Asn754, Asn793, Asn910, Asn949, Asn1046, Asn1055, Asn1075, Asn1078, Asn1175, Asn1193, Asn1229, Asn1238, Asn1265, Asn1283, Asn1310, Asn1319, Asn1347, Asn1356, Asn1451, Asn1471, Asn1531, Asn1675, Asn1982, Asn2181 <i>Phosphorylation</i> : Ser692 for platelet casein kinase II, at least two sites on the light chain for protein kinase C <i>Sulfation</i> : Tyr665, Tyr696, Tyr698, Tyr1494, Tyr1510, Tyr1515, Tyr1565
Factor VIII	<i>N-glycosylation</i> : Asn41, Asn239, Asn582, Asn757, Asn784, Asn828, Asn900, Asn943, Asn963, Asn1001, Asn1055, Asn1066, Asn1185, Asn1255, Asn1259, Asn1282, Asn1300, Asn1384, Asn1412, Asn1442, Asn1512, Asn1685, Asn1810, Asn2118 <i>Phosphorylation</i> : Thr351, Ser1657 <i>Sulfation</i> : Tyr346, Tyr718, Tyr719, Tyr723, Tyr1664, Tyr1680
Factor VII	<i>γ-carboxylation</i> : Glu6, Glu7, Glu14, Glu16, Glu19, Glu20, Glu25, Glu26, Glu29, Glu35 <i>β-hydroxylation</i> : Asp63 <i>N-glycosylation</i> : Asn145, Asn322 <i>O-glycosylation</i> : (-Glc): Ser52, (-Fuc): Ser60
Factor IX	<i>γ-carboxylation</i> : Glu7, Glu8, Glu15, Glu17, Glu20, Glu21, Glu26, Glu27, Glu30, Glu33, Glu36, Glu40 <i>β-hydroxylation</i> : Asp64 <i>N-glycosylation</i> : Asn157, Asn167 <i>O-glycosylation</i> (-GalNAc): Thr159, Thr169, Thr172, Thr179, (-Glc): Ser53, (-Fuc): Ser61 <i>Phosphorylation</i> : Ser158 <i>Sulfation</i> : Tyr155
Factor X	<i>γ-carboxylation</i> : Glu6, Glu7, Glu14, Glu16, Glu19, Glu20, Glu25, Glu26, Glu29, Glu32, Glu39 <i>β-hydroxylation</i> : Asp63 <i>N-glycosylation</i> : Asn181, Asn191 <i>O-glycosylation</i> : Thr159, Thr171, Thr443
Prothrombin	<i>γ-carboxylation</i> : Glu6, Glu7, Glu14, Glu16, Glu19, Glu20, Glu25, Glu26, Glu29, Glu32 <i>N-glycosylation</i> : Asn78, Asn100, Asn373
Protein C	<i>γ-carboxylation</i> : Glu6, Glu7, Glu14, Glu16, Glu19, Glu20, Glu25, Glu26, Glu29 <i>β-hydroxylation</i> : Asp71 <i>N-glycosylation</i> : Asn97, Asn248, Asn313, Asn329
Protein Z	<i>γ-carboxylation</i> : Glu7, Glu8, Glu11, Glu15, Glu17, Glu20, Glu21, Glu26, Glu27, Glu30, Glu33, Glu35, Glu40 <i>β-hydroxylation</i> : Asp64 <i>N-glycosylation</i> : Asn59, Asn185, Asn193, Asn266, Asn292 <i>O-glycosylation</i> : Ser53, Thr72, Ser196, Thr275
Protein S	<i>γ-carboxylation</i> : Glu6, Glu7, Glu14, Glu16, Glu19, Glu20, Glu25, Glu26, Glu29, Glu32, Glu36 <i>β-hydroxylation</i> : Asp95, Asn136, Asn178, Asn217 <i>N-glycosylation</i> : Asn458, Asn468, Asn489
Antithrombin	<i>N-glycosylation</i> : Asn96, Asn135, Asn155, Asn192
Protein C inhibitor	<i>N-glycosylation</i> : Asn230, Asn243, Asn319
von Willebrand factor	<i>N-glycosylation</i> : Asn94, Asn384*, Asn468*, Asn752, Asn811, Asn1460, Asn1527, Asn1594, Asn1637, Asn1783, Asn1822, Asn2027 <i>O-glycosylation</i> : Thr485, Thr492, Thr493, Ser500, Thr705, Thr714, Ser723, Thr724, Thr916, Thr1535 <i>Sulfation of carbohydrates</i> : Asn384, Asn468

The table is based on information obtained from the online database SWISS-PROT.






Figure 1

A

FV




FVa




B

FVIII



FVIIIa






Figure3

A

	ω -loop										disulfide loop										hydrophobic stack region																			
	1										20										30										40									
FVII	ANA-FL	Y	Y	LRPGSL	Y	R	Y	CK	Y	Y	QCSF	Y	Y	AR	Y	IFKDA	Y	RTKLF	W	I	S	Y	S																	
FIX	YNSGKL	Y	Y	FVQGNL	Y	R	Y	CM	Y	Y	KCSF	Y	Y	AR	Y	VF	Y	NT	Y	RTT	Y	FWKQ	Y	V																
FX	ANS-FL	Y	Y	MKKGHL	Y	R	Y	CM	Y	Y	TCSY	Y	Y	AR	Y	VF	Y	DSDKTN	Y	FWNK	Y	K	K																	
PT	ANT-FL	Y	Y	VRKGNL	Y	R	Y	CV	Y	Y	TCSY	Y	Y	AF	Y	AL	Y	SSTATD	V	FWAK	Y	T	T																	
PC	ANS-FL	Y	Y	LRHSSL	Y	R	Y	CI	Y	Y	ICDF	Y	Y	AK	Y	IFQNVDD	T	LAFWS	K	H	V	V																		
PZ	AGSYLL	Y	Y	LF	Y	GNL	Y	K	Y	CY	Y	Y	ICVY	Y	AR	Y	VF	Y	N	Y	VVT	Y	D	F	W	R	Y	K												
PS	ANS-LL	Y	Y	TKQGNL	Y	R	Y	CI	Y	Y	LCNK	Y	Y	AR	Y	VF	Y	NDP	Y	TDYF	Y	P	K	Y	L															

B




Figure 4






Figure5

A



B




Figure 6




Figure7